Published in Curr HIV Res on September 01, 2011
Strategic Timing of Antiretroviral Treatment (START) | NCT00867048
Uptake of home-based voluntary HIV testing in sub-Saharan Africa: a systematic review and meta-analysis. PLoS Med (2012) 2.60
HPTN 071 (PopART): a cluster-randomized trial of the population impact of an HIV combination prevention intervention including universal testing and treatment: mathematical model. PLoS One (2014) 1.66
HIV testing in re-education through labour camps in Guangxi Autonomous Region, China (a cross-sectional survey). Sex Transm Infect (2015) 1.38
Combination prevention: new hope for stopping the epidemic. Curr HIV/AIDS Rep (2013) 1.36
Client characteristics and acceptability of a home-based HIV counselling and testing intervention in rural South Africa. BMC Public Health (2012) 1.36
Effect of home based HIV counselling and testing intervention in rural South Africa: cluster randomised trial. BMJ (2013) 1.30
Can combination prevention strategies reduce HIV transmission in generalized epidemic settings in Africa? The HPTN 071 (PopART) study plan in South Africa and Zambia. J Acquir Immune Defic Syndr (2013) 1.23
Educational intervention increased referrals to allopathic care by traditional healers in three high HIV-prevalence rural districts in Mozambique. PLoS One (2013) 1.01
Clinical uncertainties, health service challenges, and ethical complexities of HIV "test-and-treat": a systematic review. Am J Public Health (2013) 0.90
Incremental cost per newly diagnosed HIV infection (NDHI): routine (RTS), targeted (TTS), and current clinical practice testing strategies (CPTS). J Int AIDS Soc (2014) 0.85
Global HIV epidemiology: A guide for strategies in prevention and care. Curr HIV/AIDS Rep (2014) 0.85
Effectiveness of a combination prevention strategy for HIV risk reduction with men who have sex with men in Central America: a mid-term evaluation. BMC Public Health (2014) 0.85
Evaluating the Impact of Test-and-Treat on the HIV Epidemic among MSM in China Using a Mathematical Model. PLoS One (2015) 0.85
Challenges in initiating antiretroviral therapy for all HIV-infected people regardless of CD4 cell count. Infect Dis Poverty (2016) 0.84
Induction of Potent and Long-Lived Antibody and Cellular Immune Responses in the Genitorectal Mucosa Could be the Critical Determinant of HIV Vaccine Efficacy. Front Immunol (2014) 0.81
Comparison of routine versus targeted HIV testing strategies: coverage and estimated missed infections in emergency room and primary care centre. J Int AIDS Soc (2014) 0.77
Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (2011) 69.36
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med (2005) 42.71
Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet (2007) 38.98
Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet (2007) 37.69
Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep (2006) 37.28
Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet (2008) 36.01
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science (2010) 35.19
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62
CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med (2006) 22.76
Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis (2005) 21.08
Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet (1995) 21.03
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet (2010) 16.90
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet (2009) 14.01
Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One (2010) 10.39
Rates, barriers and outcomes of HIV serostatus disclosure among women in developing countries: implications for prevention of mother-to-child transmission programmes. Bull World Health Organ (2004) 8.76
Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis (2004) 8.30
Universal voluntary testing and treatment for prevention of HIV transmission. JAMA (2009) 7.20
The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet (2006) 7.17
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis (2008) 6.73
A systematic review of task- shifting for HIV treatment and care in Africa. Hum Resour Health (2010) 6.48
Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. AIDS Res Hum Retroviruses (2001) 6.00
The utilization of testing and counseling for HIV: a review of the social and behavioral evidence. Am J Public Health (2007) 5.50
Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding. AIDS (2007) 4.74
Community-based intervention to increase HIV testing and case detection in people aged 16-32 years in Tanzania, Zimbabwe, and Thailand (NIMH Project Accept, HPTN 043): a randomised study. Lancet Infect Dis (2011) 4.72
HIV voluntary counseling and testing and behavioral risk reduction in developing countries: a meta-analysis, 1990--2005. AIDS Behav (2007) 4.61
Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis (2010) 4.56
Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One (2009) 4.52
Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial. Lancet (2009) 4.33
Weighing the gold in the gold standard: challenges in HIV prevention research. AIDS (2010) 4.20
Rethinking prevention of HIV type 1 infection. Clin Infect Dis (2010) 4.19
Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings. AIDS (2010) 4.05
Unfinished business--expanding HIV testing in developing countries. N Engl J Med (2006) 3.48
Limitations of rapid HIV-1 tests during screening for trials in Uganda: diagnostic test accuracy study. BMJ (2007) 3.41
Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis (2008) 3.38
Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. J Infect Dis (2008) 3.35
Evaluation of a home-based voluntary counselling and testing intervention in rural Uganda. Health Policy Plan (2005) 3.30
Barriers to access to antiretroviral treatment in developing countries: a review. Trop Med Int Health (2008) 3.01
Distribution of antiretroviral treatment through self-forming groups of patients in Tete Province, Mozambique. J Acquir Immune Defic Syndr (2011) 2.97
Comparison of home and clinic-based HIV testing among household members of persons taking antiretroviral therapy in Uganda: results from a randomized trial. J Acquir Immune Defic Syndr (2010) 2.83
Combination HIV prevention: significance, challenges, and opportunities. Curr HIV/AIDS Rep (2011) 2.72
Uptake of workplace HIV counselling and testing: a cluster-randomised trial in Zimbabwe. PLoS Med (2006) 2.71
Transmission of HIV-1 during primary infection: relationship to sexual risk and sexually transmitted infections. AIDS (2005) 2.51
Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. J Acquir Immune Defic Syndr (2002) 2.48
Design and analysis issues in cluster-randomized trials of interventions against infectious diseases. Stat Methods Med Res (2000) 2.36
Community engagement in health research: two decades of experience from a research project on HIV in rural Uganda. Trop Med Int Health (2009) 2.33
Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis (2010) 2.28
HIV incidence during a cluster-randomized trial of two strategies providing voluntary counselling and testing at the workplace, Zimbabwe. AIDS (2007) 2.15
Rapid implementation of an integrated large-scale HIV counseling and testing, malaria, and diarrhea prevention campaign in rural Kenya. PLoS One (2010) 2.12
Sensitivity of five rapid HIV tests on oral fluid or finger-stick whole blood: a real-time comparison in a healthcare setting. PLoS One (2010) 2.10
Integration of tuberculosis and HIV services in sub-Saharan Africa: lessons learned. Clin Infect Dis (2010) 2.10
Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults. Cochrane Database Syst Rev (2010) 1.94
Integrating tuberculosis and HIV care in the primary care setting in South Africa. Trop Med Int Health (2004) 1.89
High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection. J Virol (2009) 1.82
Treating our way out of the HIV pandemic: could we, would we, should we? Lancet (2008) 1.78
The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS (2005) 1.72
Episodic antiretroviral therapy increases HIV transmission risk compared with continuous therapy: results of a randomized controlled trial. J Acquir Immune Defic Syndr (2008) 1.70
Selection of HIV variants with signature genotypic characteristics during heterosexual transmission. J Infect Dis (2009) 1.67
Association of schistosomiasis with false-positive HIV test results in an African adolescent population. J Clin Microbiol (2010) 1.59
HIV counseling and testing: less targeting, more testing. Am J Public Health (2006) 1.59
Should we try to eliminate HIV epidemics by using a 'Test and Treat' strategy? AIDS (2010) 1.57
Predicting the impact of antiretrovirals in resource-poor settings: preventing HIV infections whilst controlling drug resistance. Curr Drug Targets Infect Disord (2003) 1.55
Integration of antiretroviral treatment within antenatal care in Gauteng Province, South Africa. J Acquir Immune Defic Syndr (2006) 1.55
Field evaluation of five rapid diagnostic tests for screening of HIV-1 infections in rural Rakai, Uganda. Int J STD AIDS (2011) 1.49
Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies. AIDS (2003) 1.45
Integrating prevention of mother-to-child HIV transmission (PMTCT) programmes with other health services for preventing HIV infection and improving HIV outcomes in developing countries. Cochrane Database Syst Rev (2011) 1.41
Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts. AIDS (2010) 1.41
HIV-1 transmission after cessation of early antiretroviral therapy among men having sex with men. AIDS (2010) 1.38
Cost-effectiveness of laboratory monitoring in sub-Saharan Africa: a review of the current literature. Clin Infect Dis (2010) 1.38
Do targeted HIV programs improve overall care for pregnant women?: Antenatal syphilis management in Zambia before and after implementation of prevention of mother-to-child HIV transmission programs. J Acquir Immune Defic Syndr (2008) 1.29
Evaluation of a rapid and simple fourth-generation HIV screening assay for qualitative detection of HIV p24 antigen and/or antibodies to HIV-1 and HIV-2. J Virol Methods (2010) 1.25
Point-of-care testing. Curr HIV/AIDS Rep (2011) 1.24
The impact of provider-initiated (opt-out) HIV testing and counseling of patients with sexually transmitted infection in Cape Town, South Africa: a controlled trial. Implement Sci (2010) 1.21
The nephrotoxic effects of HAART. Nat Rev Nephrol (2009) 1.20
Primary HIV infection: to treat or not to treat? Curr Opin Infect Dis (2008) 1.18
Minimizing resistance consequences after virologic failure on initial combination therapy: a systematic overview. J Acquir Immune Defic Syndr (2006) 1.17
Australian men who have sex with men prefer rapid oral HIV testing over conventional blood testing for HIV. Int J STD AIDS (2010) 1.17
The cost-effectiveness of symptom-based testing and routine screening for acute HIV infection in men who have sex with men in the USA. AIDS (2011) 1.14
Impact of acyclovir on genital and plasma HIV-1 RNA, genital herpes simplex virus type 2 DNA, and ulcer healing among HIV-1-infected African women with herpes ulcers: a randomized placebo-controlled trial. J Infect Dis (2009) 1.14
Developing an evidence-based, preventive care package for persons with HIV in Africa. Trop Med Int Health (2005) 1.13
Amplified HIV transmission during early-stage infection. J Infect Dis (2006) 1.12
Rethinking HIV exceptionalism: the ethics of opt-out HIV testing in sub-Saharan Africa. Bull World Health Organ (2010) 1.12
HIV-1 transmission biology: selection and characteristics of infecting viruses. J Infect Dis (2010) 1.11
The benefits of early treatment for HIV. AIDS (2010) 1.11
Routine, rapid HIV testing. AIDS Educ Prev (2006) 1.11
Sensitivity and specificity of HIV rapid tests used for research and voluntary counselling and testing. East Afr Med J (2008) 1.09
Antiretroviral therapy for HIV prevention: many concerns and challenges, but are there ways forward in sub-Saharan Africa? Trans R Soc Trop Med Hyg (2010) 1.05
Voluntary counseling and testing by nurse counselors: what is the role of routine repeated testing after a negative result? Clin Infect Dis (2006) 1.04
Costs of eliminating HIV in South Africa have been underestimated. Lancet (2010) 1.03
Impact of metabolic complications on antiretroviral treatment adherence: clinical and public health implications. Curr HIV/AIDS Rep (2009) 1.02
Modelling sexual transmission of HIV: testing the assumptions, validating the predictions. Curr Opin HIV AIDS (2010) 1.01
Meta-analytical studies on the epidemiology, prevention, and treatment of human immunodeficiency virus infection. Infect Dis Clin North Am (2009) 0.99
When to start antiretroviral therapy. Curr HIV/AIDS Rep (2010) 0.97
Teratogenicity risk of antiretroviral therapy in pregnancy. Curr HIV/AIDS Rep (2007) 0.97
Estimating the optimal CD4 count for HIV-infected persons to start antiretroviral therapy. Epidemiology (2010) 0.96
HIV prevention in sub-Saharan Africa: a multilevel analysis of message frames and their social determinants. Health Promot Int (2007) 0.92
Quantifying the risks and benefits of efavirenz use in HIV-infected women of childbearing age in the USA. HIV Med (2011) 0.89
AZT: an old drug with new perspectives. Curr Clin Pharmacol (2008) 0.88
Longitudinal effect following initiation of highly active antiretroviral therapy on plasma and cervico-vaginal HIV-1 RNA among women in Burkina Faso. Sex Transm Infect (2007) 0.87
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Short-course antiretroviral therapy in primary HIV infection. N Engl J Med (2013) 4.82
Adaptation of HIV-1 to human leukocyte antigen class I. Nature (2009) 4.24
Uptake of home-based voluntary HIV testing in sub-Saharan Africa: a systematic review and meta-analysis. PLoS Med (2012) 2.60
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med (2012) 2.24
Adherence to antiretroviral therapy in adolescents living with HIV: systematic review and meta-analysis. AIDS (2014) 2.10
Quantifying sexual exposure to HIV within an HIV-serodiscordant relationship: development of an algorithm. AIDS (2011) 2.10
Ultrasensitive detection and phenotyping of CD4+ T cells with optimized HLA class II tetramer staining. J Immunol (2005) 1.94
Reductions in HIV transmission risk behaviour following diagnosis of primary HIV infection: a cohort of high-risk men who have sex with men. HIV Med (2009) 1.83
Failure to detect xenotropic murine leukemia virus-related virus in blood of individuals at high risk of blood-borne viral infections. J Infect Dis (2010) 1.62
Antiviral inhibitory capacity of CD8+ T cells predicts the rate of CD4+ T-cell decline in HIV-1 infection. J Infect Dis (2012) 1.61
Similar mortality and reduced loss to follow-up in integrated compared with vertical programs providing antiretroviral treatment in sub-saharan Africa. J Acquir Immune Defic Syndr (2012) 1.58
Incidence of tuberculosis in HIV-infected patients before and after starting combined antiretroviral therapy in 8 sub-Saharan African HIV programs. J Acquir Immune Defic Syndr (2011) 1.45
Cytomegalovirus retinitis: the neglected disease of the AIDS pandemic. PLoS Med (2007) 1.33
Impaired IFN-gamma-secreting capacity in mycobacterial antigen-specific CD4 T cells during chronic HIV-1 infection despite long-term HAART. AIDS (2006) 1.30
Provision of antiretroviral treatment in conflict settings: the experience of Médecins Sans Frontières. Confl Health (2010) 1.25
Survival following HIV infection of a cohort followed up from seroconversion in the UK. AIDS (2008) 1.23
Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection. PLoS One (2012) 1.22
Tracking virus-specific CD4+ T cells during and after acute hepatitis C virus infection. PLoS One (2007) 1.16
HIV-1-specific CD4+ T lymphocyte turnover and activation increase upon viral rebound. J Clin Invest (2005) 1.15
Sexual transmission of HIV-1. Antiviral Res (2009) 1.13
Duration of HIV-1 viral suppression on cessation of antiretroviral therapy in primary infection correlates with time on therapy. PLoS One (2013) 1.11
Antiretroviral treatment of primary HIV infection to reduce onward transmission. Curr Opin HIV AIDS (2010) 1.11
Optimizing antiretroviral therapy in adolescents with perinatally acquired HIV-1 infection. Expert Rev Anti Infect Ther (2010) 1.06
Differences in HIV-specific T cell responses between HIV-exposed and -unexposed HIV-seronegative individuals. J Virol (2011) 1.02
Crossing the divide: transition care services for young people with HIV-their views. AIDS Patient Care STDS (2011) 1.00
Epidemiology of non-B clade forms of HIV-1 in men who have sex with men in the UK. AIDS (2010) 1.00
The detection and management of early HIV infection: a clinical and public health emergency. J Acquir Immune Defic Syndr (2013) 0.98
HIV-1-specific CD4(+) responses in primary HIV-1 infection predict disease progression. AIDS (2014) 0.97
A systematic review of definitions of extreme phenotypes of HIV control and progression. AIDS (2014) 0.96
High rates of asymptomatic neurocognitive impairment in vertically acquired HIV-1-infected adolescents surviving to adulthood. J Acquir Immune Defic Syndr (2010) 0.95
Increasing incidence of acute hepatitis C in individuals diagnosed with primary HIV in the United Kingdom. AIDS (2008) 0.94
HIV prevention 2010: where are we now and where are we going? Curr Opin HIV AIDS (2010) 0.91
"Payment by Results"--financial incentives and motivational interviewing, adherence interventions in young adults with perinatally acquired HIV-1 infection: a pilot program. AIDS Patient Care STDS (2014) 0.91
Role of HIV infection duration and CD4 cell level at initiation of combination anti-retroviral therapy on risk of failure. PLoS One (2013) 0.90
Interleukin-6 and D-dimer levels at seroconversion as predictors of HIV-1 disease progression. AIDS (2014) 0.90
Intimate relationships in young adults with perinatally acquired HIV: partner considerations. AIDS Care (2012) 0.90
Phylogenetic analysis consistent with a clinical history of sexual transmission of HIV-1 from a single donor reveals transmission of highly distinct variants. Retrovirology (2011) 0.89
Advancing the HIV cure agenda: the next 5 years. Curr Opin Infect Dis (2015) 0.89
Laboratory adverse events and discontinuation of therapy according to CD4(+) cell count at the start of antiretroviral therapy. AIDS (2014) 0.87
Human immunodeficiency virus (HIV)-specific T helper responses fail to predict CD4+ T cell decline following short-course treatment at primary HIV-1 infection. Clin Exp Immunol (2008) 0.87
Low levels of HIV test coverage in clinical settings in the U.K.: a systematic review of adherence to 2008 guidelines. Sex Transm Infect (2014) 0.87
Clinical evaluation of the Determine HIV-1/2 Ag/Ab Combo test. J Infect Dis (2012) 0.87
Prevalence of primary genotypic resistance in a UK centre: Comparison of primary HIV-1 and newly diagnosed treatment-naive individuals. AIDS (2007) 0.86
Increased levels of CD4 T-cell activation in individuals with CXCR4 using viruses in primary HIV-1 infection. AIDS (2012) 0.83
Parenting considerations in young adults with perinatally acquired HIV. AIDS Care (2013) 0.81
Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies. J Antimicrob Chemother (2011) 0.81
Sexual and reproductive health in a UK cohort of young adults perinatally infected with HIV. Sex Transm Infect (2013) 0.81
Comparison of sexual behavior and HIV risk between two HIV-1 serodiscordant couple cohorts: the CHAVI 002 study. PLoS One (2012) 0.80
Assessment of Anti-HIV-1 Antibodies in Oral and Nasal Compartments of Volunteers From 3 Different Populations. J Acquir Immune Defic Syndr (2016) 0.79
Community intervention improves knowledge of HIV status of adolescents in Zambia: findings from HPTN 071-PopART for youth study. AIDS (2017) 0.78
The effect of short-course antiretroviral therapy initiated in primary HIV-1 infection on interleukin-6 and D-dimer levels. AIDS (2015) 0.77
Post-treatment control or treated controllers? Viral remission in treated and untreated primary HIV infection. AIDS (2017) 0.77
Brief Report: Enhanced Normalization of CD4/CD8 Ratio With Earlier Antiretroviral Therapy at Primary HIV Infection. J Acquir Immune Defic Syndr (2016) 0.77
Longitudinal analysis of an HLA-B*51-restricted epitope in integrase reveals immune escape in early HIV-1 infection. AIDS (2013) 0.76
Could we, should we? Yes. AIDS (2011) 0.76
Mean Corpuscular Volume as a Marker for Adherence to Zidovudine-Containing Therapy in HIV-Infected Adults. Open AIDS J (2012) 0.75
Resistance to HIV drugs in UK may be lower in some areas. BMJ (2006) 0.75
Risk of HIV transmission in discordant partners. J HIV Ther (2007) 0.75
HIV cure strategies: response to ignore the central nervous system at your patients' peril. AIDS (2017) 0.75
What works-reaching universal hiv testing: lessons from HPTN 071 (PopART) trial in Zambia. AIDS (2017) 0.75
Hepatocellular Carcinoma in Perinatally Acquired HIV and HBV Co-Infection: A Case Report. Pediatr Infect Dis J (2017) 0.75
Early antiretroviral therapy reduces hiv dna following perinatal HIV infection. AIDS (2017) 0.75
Cerebral function in perinatally HIV-infected young adults and their HIV-uninfected sibling controls. HIV Clin Trials (2015) 0.75
Baseline CD4 Count and Adherence to Antiretroviral Therapy: A Systematic Review and Meta-Analysis. J Acquir Immune Defic Syndr (2016) 0.75